Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM – Get Rating)'s stock price was up 2% during trading on Tuesday . The stock traded as high as $2.64 and last traded at $2.55. Approximately 125,887 shares traded hands during trading, an increase of 180% from the average daily volume of 44,959 shares. The stock had previously closed at $2.50.
Reneo Pharmaceuticals Stock Up 2.0 %
The company's 50 day moving average price is $2.30 and its 200 day moving average price is $2.91. The firm has a market capitalization of $62.55 million, a price-to-earnings ratio of -1.28 and a beta of 0.50.
Get Reneo Pharmaceuticals alerts:Reneo Pharmaceuticals (NASDAQ:RPHM – Get Rating) last issued its earnings results on Tuesday, November 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.05. As a group, analysts expect that Reneo Pharmaceuticals, Inc. will post -2.16 earnings per share for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in RPHM. Renaissance Technologies LLC purchased a new position in shares of Reneo Pharmaceuticals during the second quarter worth $61,000. Dimensional Fund Advisors LP purchased a new position in shares of Reneo Pharmaceuticals during the third quarter worth $62,000. Federated Hermes Inc. increased its holdings in Reneo Pharmaceuticals by 76.5% in the second quarter. Federated Hermes Inc. now owns 30,000 shares of the company's stock valued at $80,000 after buying an additional 13,000 shares in the last quarter. Bank of America Corp DE raised its position in shares of Reneo Pharmaceuticals by 24.0% in the first quarter. Bank of America Corp DE now owns 40,878 shares of the company's stock worth $121,000 after acquiring an additional 7,914 shares during the period. Finally, UBS Group AG boosted its stake in shares of Reneo Pharmaceuticals by 5,012.5% during the 2nd quarter. UBS Group AG now owns 54,550 shares of the company's stock worth $145,000 after acquiring an additional 53,483 shares in the last quarter. Hedge funds and other institutional investors own 75.61% of the company's stock.About Reneo Pharmaceuticals
(Get Rating)
Reneo Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.
Further Reading
- Get a free copy of the StockNews.com research report on Reneo Pharmaceuticals (RPHM)
- EVgo Stock is Charged Up to Ride the EV Adoption Wave
- Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
- High-Yield, Deep-Value Verizon Puts In A Bottom
- Can Coty Stock Emerge in 2023 With Upside
- Should You Bet Against The Nasdaq 100 With This Inverse ETF?
Receive News & Ratings for Reneo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reneo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.